To print: Select File and then Print from your browser's menu

Title: Divided Vinorelbine With Methotrexate/Fluorouracil Effective In Metastatic Breast Cancer

URL: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=R
Retrieve&db=PubMed&list_uids=12702522&dopt=Abstract

Annals of Oncology 2003;14:5:699-703. "Vinorelbine, methotrexate and fluorouracil (VMF) as first-line therapy in metastatic breast cancer: a randomized phase II trial"
04/29/2003 03:02:35 PM
By Elda Hauschildt

Combination regimens that include vinorelbine, divided between days 1 and 8 of a 3-week cycle, are comparable in efficacy to other modern first-line regimens in treating metastatic breast cancer. In this 2-step study, Finnish researchers used 3 vinorelbine to determine the best tolerated dose to combine with methotrexate at 40 mg/m[² on day 1 and fluorouracil at 600 mg/m² on days 1 and 8 in patients with evaluable metastases. The first step involved 30 patients, randomly allocated to 1 of 3 vinorelbine groups: 20 mg/m² on days 1 and 8, 30 mg/m² on 1 and 10 mg/m² on day 8 or 40 mg/m² on day 1 but not exceeding 60 mg/m². In the second step of the study, the worst tolerated regimen was excluded, and the study was expanded to include 60 patients. Objective response rates were seen in 50% of patients receiving 20 plus 20 mg/m² vinorelbine, 55% of those receiving 30 plus 10 mg/m² doses and 44% of those receiving 40 mg/m² doses. Median time to survival was 26 months in the 20 plus 20 mg/m² vinorelbine group, 23 months in the 30 plus 10 mg/m² group and 16 months in the 40 mg/m² group. Median time to progression was 7 months in the 20 plus 20 mg/m² vinorelbine group, 10 months in the 30 plus 10 mg/m² group and eight months in the 40 mg/m² group. Haematological toxicity was measured using World Health Organisation definitions. Grade 3 toxicity was seen in 23% of patients receiving the 20 plus 20 mg/m²doses, 36% of those receiving 30 plus 10 mg/m² doses and 50% of those receiving 40 mg/m² doses.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=R
Retrieve&db=PubMed&list_uids=12702522&dopt=Abstract

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.